SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 7, 2019
ARCTURUS THERAPEUTICS HOLDINGS INC.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
10628 Science Center Drive, Suite 250
San Diego, California 92121
(Address of principal executive offices)
Registrants telephone number, including area code: (858) 900-2660
Arcturus Therapeutics Ltd.
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
on which registered
|Common stock, par value $0.001 per share||ARCT||The NASDAQ Stock Market LLC|
|Item 7.01|| |
Regulation FD Disclosure
Arcturus Therapeutics Holdings Inc. (the Company) has made available a presentation about the Companys business (the Presentation), a copy of which is filed as Exhibit 99.1 to this Current Report on Form 8-K (the Report) and is hereby incorporated by reference.
The furnishing of the Presentation is not an admission as to the materiality of any information therein. The information contained in the Presentation is summary information that should be considered in the context of the Companys filings with the Securities and Exchange Commission (the SEC) and other public announcements the Company may make by press release or otherwise from time to time. The Presentation speaks as of the date of this Report. While the Company may elect to update the Presentation in the future to reflect events and circumstances occurring or existing after the date of this Report, the Company specifically disclaims any obligation to do so.
The Presentation contains forward-looking statements, and as a result, investors should not place undue reliance on these forward-looking statements.
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this communication and the Presentation are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements about: expectations regarding our capitalization, strategy, future operations, collaborations or resources; the adequacy of our capital to support our future operations and our ability to successfully initiate and complete clinical trials; our strategy and focus; the development and commercial potential of any of our product candidates; the timing and success of our development efforts; the success of any of our trials and our ability to achieve regulatory approval for any product candidate; the entry into, modification or termination of collaborative agreements; the date that an IND may be filed with the FDA; the potential market or success for the clinical development programs of the Company; the likelihood of success of the Companys technology or potential development of any of the Companys products, preclinical or clinical development programs; the expected employment of key personnel; the yield of preventative and therapeutic treatments or commercial or therapeutic success of the Companys products or programs, including those for the treatment of cystic fibrosis; or any statements other than statements of historical fact, including those related to the Companys future cash, market or financial position. These forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. Forward-looking statements speak only as of the date they are made and the Company assumes no duty to update forward-looking statements, except as required by law.
In addition to factors previously disclosed in the Companys reports filed with the SEC and those identified elsewhere in this communication, the following factors, among others, could cause actual results to differ materially from forward-looking statements and historical performance: the availability and access, in general, of funds to fund operations and necessary capital expenditures, the strength of our intellectual property portfolio, the expected safety profiles of our product candidates, the proof of concept of our product candidates, the target opportunities for certain of our product candidates, our expected dates of submission of one or more Investigational New Drug Applications to the FDA, market opportunities with respect to certain diseases connected with our product candidates, manufacturing and formulation capabilities of the Company or our manufacturing partners with respect to our product candidates, as well as our managements response to the preceding factors. The foregoing factors are in addition to the other factors set forth in the Companys reports on Form 10-K, Form 8-K, and other documents on file with the SEC.
Other risks and uncertainties are more fully described under the heading Risk Factors in the Companys Annual Report on Form 10-K for the fiscal year ended December 31, 2018, filed with the SEC on March 18, 2019, and in other filings that the Company makes and will make with the SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The statements made in this Current Report on Form 8-K and the exhibit(s) attached hereto speak only as of the date stated herein, and subsequent events and developments may cause the Companys expectations and beliefs to change. While the Company may elect to update these forward-looking statements publicly at some point in the future, the Company specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the Companys views as of any date after the date stated herein.
|Item 9.01|| |
Financial Statements and Exhibits.
|99.1||Presentation of Arcturus Therapeutics Holdings Inc., dated November 2019|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Arcturus Therapeutics Holdings Inc.|
|Date: November 7, 2019|
|Name:||Joseph E. Payne|
|Title:||Chief Executive Officer|
Building the Next Generation of RNA Medicines ARCTURUS THERAPEUTICS November 2019 Exhibit 99.1
FORWARD LOOKING STATEMENTS ARCTURUS THERAPEUTICS This presentation contains forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future performances or achievements expressed or implied by the forward-looking statements. Each of these statements is based only on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements about: expectations regarding our capitalization and resources; the adequacy of our capital to support our future operations and our ability to successfully initiate and complete clinical trials; our strategy and focus; the development and commercial potential of any of our product candidates; the timing and success of our development efforts; the success of any of our trials and our ability to achieve regulatory approval for any product candidate; the entry into or modification or termination of collaborative agreements; the date that an IND may be filed with the FDA; the potential market or clinical or commercial success of the clinical development programs of Arcturus; and any statements other than statements of historical fact, including those related to Arcturus’ future cash, market or financial position. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential” and similar expressions (including the negative thereof) intended to identify forward looking statements. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing, and you should not place undue reliance on such forward-looking statements. The forward-looking statements contained or implied in this press presentation are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in Arcturus’ Annual Report on Form 10-K for the fiscal year ended December 31, 2018, filed with the SEC on March 18, 2019, and in subsequent filings with, or submissions to, the SEC. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. BUILDING INNOVATIVE RNA MEDICINES
Arcturus is an mRNA Medicines Drug Development Company Focused on Rare Diseases HQ: San Diego; Founded: 2013; Nasdaq: ARCT Outstanding Shares: 15.1M; Employees: 85; Insider Ownership: 33% BUILDING INNOVATIVE RNA MEDICINES Broad and Strong Intellectual Property Portfolio 177 Patents & Patent Applications LUNAR® Delivery Technology RNA Drug Substance & Drug Product Process Manufacturing Investment Highlights ARCTURUS THERAPEUTICS LUNAR® Delivery Platform Validated by Multiple Strategic Partners More than $1 Billion in potential milestones and royalties Promising Preclinical Safety Data for LUNAR® Delivery and mRNA Drug Products
Pipeline: Arcturus mRNA Medicines BUILDING INNOVATIVE RNA MEDICINES Key Value Drivers: Platform & Pipeline ARCTURUS THERAPEUTICS Platform: LUNAR® Delivery, mRNA Drug Substance, and STARR (Self-Transcribing And Replicating RNA) Technology ™ Strategic Partners: More than $1 Billion in Potential Milestones & Royalties OTC Deficiency market potential $500M annual sales LUNAR-CF to treat Cystic Fibrosis (CF); Funded by the Class I CF market potential $900M annual sales LUNAR-OTC (ARCT-810) to treat Ornithine Transcarbamylase (OTC) Deficiency Orphan Drug Designation is received from U.S. FDA
LUNAR® Mechanism of Delivery LUNAR Associates with Cell Membrane Enters Cell Via Endocytosis Lipid Particle in Endosome pH-Mediated Disruption Rapid Biodegradation of Vehicle RNA in Cytosol RNA Processing and Translation Increased Acidity as Endosome Ages ARCTURUS THERAPEUTICS BUILDING INNOVATIVE RNA MEDICINES
BUILDING INNOVATIVE RNA MEDICINES Name Partner Indication Arcturus Chemistry Arcturus Delivery mRNA Expected IND Date LUNAR-HBV Hepatitis B RNA LUNAR® Hepatocytes ARCT TBD LUNAR-NASH NASH RNA LUNAR® Stellate Cells ARCT TBD LUNAR-GSD3 Glycogen Storage Disease Type III mRNA LUNAR® Hepatocytes ARCT 2020 LUNAR-RARE Undisclosed Rare Disease mRNA LUNAR® Hepatocytes ARCT TBD LUNAR-RPL Large Pharma Infectious Disease Prophylactic Vaccines SGI’s Replicon RNA LUNAR® Undisclosed TBD LUNAR-AH Large Animal Health Pharma Infectious Disease Prophylactic Vaccines SGI’s Replicon RNA LUNAR® Undisclosed TBD Arcturus Platform: Enabling Genetic Medicines 5 ARCTURUS THERAPEUTICS Greater than $1 Billion in Potential Milestones & Royalties Enabling Different Types of RNA – Messenger RNA, Gene Editing RNA, Replicon RNA Multiple Cell Types Targeted LUNAR-GSD3 (UX053) is a licensed program, partnered with Ultragenyx – IND Target 2020
Arcturus Pipeline of mRNA Medicines Name Indication Expected IND Date Route of Administration Target Organ Target Cells Prevalence Worldwide LUNAR-OTC (ARCT-810) Ornithine Transcarbamylase (OTC) Deficiency Q1 2020 Intravenous (i.v.) Liver Hepatocytes > 10,000 LUNAR-CF Cystic Fibrosis 2021 Nebulized Aerosol to Lung Lung Bronchial Epithelial Cells > 70,000 LUNAR-CV Rare Cardiovascular Disease Preclinical Intravenous (i.v.) Liver Hepatocytes Undisclosed LUNAR-MD Rare Metabolic Disease Preclinical Intravenous (i.v.) Liver Hepatocytes Undisclosed BUILDING INNOVATIVE RNA MEDICINES ARCTURUS THERAPEUTICS Pipeline programs focus on messenger RNA (mRNA) drug products for rare diseases LUNAR-OTC (ARCT-810, intravenous mRNA medicine): IND Filing Target Q1 2020 LUNAR-CF is funded by the Cystic Fibrosis (CF) Foundation: IND Filing Target 2021 LUNAR-CV and LUNAR-MD are preclinical programs
LUNAR® Platform Substantial Preclinical Proof-of-Concept Demonstrated Vaccines Respiratory Ophthalmology Liver Cancer Inf. Disease Infectious Disease LUNAR-CF mRNA Intratracheal Inhalation Gene Editing RNA mRNA Animal Health mRNA Shared Antigens Ultragenyx LUNAR-GSD3 mRNA Takeda LUNAR-NASH LUNAR-OTC (ARCT-810) mRNA mRNA Intravitreal Sub-retinal Janssen siRNA triplicate Hepatocytes Stellate Cells LUNAR® Platform Preclinical Proof-of-Concept Demonstrated in Hepatocytes, Liver Stellate Cells, Bronchial Epithelial Cells (Lung), Photoreceptors (Eye), Infectious Diseases, Cancer Vaccines BUILDING INNOVATIVE RNA MEDICINES mRNA Neoantigens 7 ARCTURUS THERAPEUTICS
Target Opportunities for LUNAR® Delivery Platform Exceed $100 Billion in Potential Value Immuno-oncology Vaccines Immune System Infectious Disease mRNA geRNA DNA Lung Eye Oral Kidney Spleen Brain Liver mRNA geRNA DNA mRNA geRNA DNA mRNA geRNA DNA mRNA geRNA DNA mRNA geRNA DNA mRNA geRNA DNA geRNA DNA mRNA geRNA DNA mRNA geRNA DNA mRNA mRNA Non- Vaccines Non- Vaccines Vaccines Topical mRNA BUILDING INNOVATIVE RNA MEDICINES ARCTURUS THERAPEUTICS
OTC Deficiency Market Opportunity LUNAR-OTC Aims to Restore Enzyme Function Expression of OTC enzyme in liver has potential to restore normal urea cycle activity to detoxify ammonia, preventing neurological damage and removing need for liver transplantation Unmet Medical Need Present standard of care involves a strict diet (low protein, high fluid intake) plus ammonia scavengers (sodium phenylbutyrate) Present standard of care does not effectively prevent spikes of ammonia. OTC Deficiency patients are typically referred for liver transplant. Ornithine Transcarbamylase (OTC) Deficiency: The most common urea cycle disorder The urea cycle converts neurotoxic ammonia to water-soluble urea that can be excreted in urine Deficiency in OTC causes elevated blood ammonia, which can lead to neurological damage, coma, and death 10,000 worldwide prevalence BUILDING INNOVATIVE RNA MEDICINES ARCTURUS THERAPEUTICS
BUILDING INNOVATIVE RNA MEDICINES Disease Normalization Following Single and Repeat Dosing in OTC Mouse Model LUNAR®-OTC ARCTURUS THERAPEUTICS Survival of OTC-deficient Mice on High Protein Diet - Weekly LUNAR-OTC Treatment
LUNAR-OTC 11 BUILDING INNOVATIVE RNA MEDICINES ARCTURUS THERAPEUTICS Exceeds Therapeutic Target of 10% Enzyme Replacement at all Doses in OTC-Deficient Mouse Model Therapeutic Target = 10% OTCD impacts ureagenesis (ammonia detoxification) The main site of ureagenesis is the periportal region of the liver* Establishing 10% of natural enzyme levels is expected to be therapeutically significant *Li, L. et al. PGC-1α Promotes Ureagenesis in Mouse Periportal Hepatocytes through SIRT3 and SIRT5 in Response to Glucagon. Scientific Reports. 6:24156 | DOI: 10.1038/srep24156, April 2016 *Lamers, W.H., Hakvoort, T.B.M., and Köhler, E.S. 'Molecular Pathology of Liver Diseases' in Monga S.P.S. (ed.), MOLECULAR PATHOLOGY LIBRARY SERIES, Springer Publishing, New York, pp. 125-132 | DOI: 10.1007/978-1-4419-7107-4 LUNAR-OTC treatment increases OTC expression in mouse periportal hepatocytes (main site of ureagenesis)
ATX Lipids are Effective and Degrade Rapidly ARCTURUS THERAPEUTICS BUILDING INNOVATIVE RNA MEDICINES 12 Protein Expression (in vivo) Esterase Catalyzed Degradation (in vitro) Next Generation ATX Lipids Retain Degradability & Improve Delivery Efficiency
ATX 2.0 Lipid Rapidly Clears in vivo 13 BUILDING INNOVATIVE RNA MEDICINES ARCTURUS THERAPEUTICS Plasma Liver ATX Lipid (the major component in LUNAR® technology) is rapidly degraded in vivo ATX Lipid Half-Life in the Liver is Approximately 20 hours
External Validation Multiple strategic partnerships over many years confirms the positive safety profile of Arcturus LUNAR® and mRNA Arcturus is committed to developing safe mRNA products 15 studies over several years with strategic partners Top Safety Concern for RNA Medicines is Delivery Arcturus LUNAR® Delivery Technology is well tolerated in non-human primates (NHPs) @ 15 mg/kg single dose of non-coding RNA @ 3 mg/kg x eight (8) weekly doses of non-coding RNA (total of 24 mg/kg over 2 months) Arcturus mRNA chemistry shows promising efficacy and tolerability data Efficacy of OTC mRNA in mouse model @ 0.1 – 1 mg/kg Well tolerated in mouse @ 7 mg/kg single dose IND-enabling toxicology studies at higher doses will provide Maximum Tolerated Dose (MTD) Arcturus Safety Profile 14 BUILDING INNOVATIVE RNA MEDICINES ARCTURUS THERAPEUTICS
Arcturus Therapeutics Lots produced at Arcturus Lots produced at CMO as part of recent GMP campaign mRNA Drug Substance 15 Three 12.5 g lots produced in recent campaign are of equivalent quality and yield
BUILDING INNOVATIVE RNA MEDICINES LUNAR®-mRNA Drug Product Arcturus Therapeutics 16 Scalability of Drug Product demonstrated from milligram to multigram scale with yields > 85% Multiple batches (10g) of LUNAR®-OTC mRNA manufactured
LUNAR-CF Aims to Restore CFTR Function An mRNA replacement therapy has the potential to deliver a new copy of CFTR into the lungs of CF-patients, independent of any genotype A functional CFTR protein can restore chloride channel efflux in the airways, reducing mucus accumulation, tissue scarring and minimizing the progressive respiratory dysfunction observed in CF-patients Cystic Fibrosis: The most common rare disease in the United States Caused by genetic mutations in the CFTR gene, resulting in aberrant flux of ions in and out of cells, causing thick mucus buildup in lung airways Chronic airway obstruction leads to infection and inflammation, which causes permanent tissue scarring and respiratory failure 70,000 worldwide prevalence Cystic Fibrosis Market Opportunity Unmet Medical Need No CFTR functional corrector is approved for treatment of all patients Present standard of care does not effectively prevent long-term effects of mucus accumulation. CF patients with late-stage loss of respiratory function require lung transplant BUILDING INNOVATIVE RNA MEDICINES ARCTURUS THERAPEUTICS
LUNAR® Targeting Lung LUNAR + Luciferase mRNA LUNAR® Delivery into Bronchial Epithelial Cells (BECs) Nebulization TdTomato / FoxJ1 / Dapi BUILDING INNOVATIVE RNA MEDICINES ARCTURUS THERAPEUTICS Functional Nebulized Delivery of LUNAR + mRNA into Lung Epithelial Cells
Drug Substance: mRNA Design Weekly Dosing in Non-Human Primates Arcturus’ proprietary mRNA optimization platform Optimize mRNA sequence Chemistry Process Sustained hEPO activity in NHPs upon repeat dosing BUILDING INNOVATIVE RNA MEDICINES ARCTURUS THERAPEUTICS Proprietary mRNA Optimization Platform Demonstrates Sustained Activity Upon Repeat Dosing in NHPs Improve Protein Expression Duration Functional Activity
Arcturus mRNA Manufacturing ARCTURUS THERAPEUTICS Features Benefits Optimized IVT Method Reduced Cost; Higher Purity Improved Capping Reaction Reduced Cost of Goods Proprietary Purification Process Higher Purity in a Shorter Time Efficient Entire Process Less Than One Week Scalable to > 1Kg Access Large Patient Populations Adaptable Can Utilize a Variety of Modifications BUILDING INNOVATIVE RNA MEDICINES Arcturus’ Internal mRNA Production: Up to 30 g in Less Than One Week DNA Template Production IVT and Capping Reaction Purification Process Buffer Exchange & Concentration
BUILDING INNOVATIVE RNA MEDICINES Drug Product: LUNAR® Formulation & Production LUNAR® Reproducibility LUNAR® Scalability ARCTURUS THERAPEUTICS Proprietary, Reproducible & Scalable Drug Product Production Process LUNAR-Formulated mRNA Successfully Scaled From Milligram to Multigram Batch Sizes Particle Size % Encapsulated RNA % Encapsulated RNA Particle Size
Board of Directors ARCTURUS THERAPEUTICS Dr. Peter Farrell Chairman of the Board James Barlow, MA Director of the Board Dr. Magda Marquet Director of the Board Joseph E. Payne, MSc Director of the Board, President & CEO Founder & Chairman of ResMed Former CAO of Allergan Chairman & Co-Founder of Althea BUILDING INNOVATIVE RNA MEDICINES Dr. Emil D. Kakkis Board Advisor Andrew Sassine, MBA Director of the Board, CFO Former Portfolio Manager of Fidelity Karah Parschauer, JD Director of the Board General Counsel of Ultragenyx President & CEO of Ultragenyx Dr. Edward W. Holmes Director of the Board President & CEO of Sanford Consortium
Management Team ARCTURUS THERAPEUTICS Joseph E. Payne, MSc Founder, President & CEO Andrew Sassine, MBA CFO Dr. Pad Chivukula Founder, CSO & COO Kevin Skol, MBA Sr. VP of Business Development & Alliance Management Dr. Suezanne Parker VP of Translational Biology BUILDING INNOVATIVE RNA MEDICINES